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http://dx.doi.org/10The Fanconi anemia (FA/BRCA) signaling network controls multiple genome-housekeeping
checkpoints, from interphase DNA repair to mitosis. The in vivo role of abnormal cell division
in FA remains unknown. Here, we quantified the origins of genomic instability in FA patients
and mice in vivo and ex vivo. We found that both mitotic errors and interphase DNA damage
significantly contribute to genomic instability during FA-deficient hematopoiesis and in non-
hematopoietic human and murine FA primary cells. Super-resolution microscopy coupled
with functional assays revealed that FANCA shuttles to the pericentriolar material to regulate
spindle assembly at mitotic entry. Loss of FA signaling rendered cells hypersensitive to spindle
chemotherapeutics and allowed escape from the chemotherapy-induced spindle assembly
checkpoint. In support of these findings, direct comparison of DNA crosslinking and
anti-mitotic chemotherapeutics in primary FANCA/ cells revealed genomic instability
originating through divergent cell cycle checkpoint aberrations. Our data indicate that
FA/BRCA signaling functions as an in vivo gatekeeper of genomic integrity throughout
interphase and mitosis, which may have implications for future targeted therapies in FA
and FA-deficient cancers. Copyright  2015 ISEH - International Society for Experimental
Hematology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The Fanconi anemia (FA/BRCA) pathway is an intricate
plexus of at least 17 proteins that maintain genomic stabil-
ity, control growth and development, and prevent cancer.
Bi-allelic germline disruption of any FA gene causes Fan-
coni anemia (FA), a genetic disorder characterized by
developmental abnormalities, bone marrow failure (BMF),
myelodysplasia, and high risk of cancer, particularly acute
myeloid leukemia (AML) [1–5]. Heterozygous inborn mu-
tations in the BRCA branch of the FA network increase risk
of breast and ovarian cancers as well as other tumors [5–9],
and somatic mutations of FA/BRCA genes occur in malig-
nancies in non–Fanconi patients [10–13]. Thus, disruption
of FA/BRCA signaling promotes malignancies in the in-
herited genetic syndromes and in the general population.: Grzegorz Nalepa, Herman B. Wells Center for Pe-
sion of Pediatric Hematology–Oncology, Department
University School of Medicine, 1044 West Walnut
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related to this article can be found online at http://
exphem.2015.08.013.
 2015 ISEH - International Society for Experimental Hem
se (http://creativecommons.org/licenses/by-nc-nd/4.0/).
.1016/j.exphem.2015.08.013The FA/BRCA pathway prevents cancer by protecting
genome integrity. In interphase, the DNA damage response
(DDR) initiates the assembly of the multiprotein FA com-
plex at damage sites to arrest the cell cycle as the cascade
of effectors repairs the lesions [1,5]. These compartmental-
ized bursts of FA activity handle multiple genotoxic insults,
from endogenous aldehydes [14,15] to replication errors and
mutagen exposure. Thus, the FA/BRCA network provides a
crucial line of defense against interphase mutagenesis [1,5].
Less is known about the role of the FA/BRCA pathway
during mitosis, but FA signaling has recently been impli-
cated in the maintenance of normal centrosome count
[16–19], spindle assembly checkpoint (SAC) [17,20], repair
of anaphase bridges [21,22], and execution of cytokinesis
[23–25]. Because chromosomal instability resulting from
mitotic errors is a hallmark of cancer [26,27] and a thera-
peutic target [28], these findings may have translational
relevance. However, it is unknown whether these ex vivo
observations are applicable to in vivo hematopoiesis.
Here, we present quantitative evidence that loss of FA
signaling disrupts mitosis during in vivo hematopoiesis inatology. Published by Elsevier Inc. This is an open access article under the
1032 Z. Abdul-Sater et al./ Experimental Hematology 2015;43:1031–1046humans and mice and that both aberrant interphase and
mitotic failure contribute to genomic instability caused by
FA deficiency. Super-resolution microscopy revealed that
FANCA shuttles to the pericentriolar material at mitotic
entry to regulate centrosome-associated spindle nucleation.
We found that primary FANCA/ cells escape
chemotherapy-induced SAC to replicate despite genomic
instability. Our cell survival assays indicated that
FA-deficient cells are hypersensitive to taxol (an antimitotic
chemotherapeutic agent). Sublethal taxol doses exacerbated
genomic instability in FA/ cells through mitotic errors,
whereas low-dose mitomycin C (MMC) activated the G2/M
checkpoint and DNA breakage. Therefore, distinct classes
of chemotherapeutic agents inflict unique damage patters
in FA/ cells, which may have implications for future
strategies against FA-deficient cancers. Together, our find-
ings provide insights into complex mechanisms of genomic
instability in FA.Methods
Cell culture
The primary patient fibroblast cells, FANCA/ (MNHN, RA885)
and FANCC/ (WD-C1, homozygous for FANCCc.377_378delGA),
were received from Dr. Helmut Hanenberg (Indiana University
[IU]). MNHN cells harbor two FANCA mutations: c.3163COT
and c.4124-4125delCA. Both FANCA-deficient lines have been
described and the functional gene correction of all cell lines used
in this study has been validated in G2/M MMC hypersensitivity as-
says (Supplementary Figure E1, online only, available at www.
exphem.org) [17]. Experiments were done using MNHN cells un-
less otherwise noted. Fibroblasts and mouse embryonic fibroblasts
(MEFs) were cultured in Dulbecco’s modified Eagle medium
(DMEM) containing 10% fetal bovine serum (FBS), 1% peni-
cillin–streptomycin (pen-strep), and 1% sodium pyruvate in 37C
5% CO2/5% O2 incubators to minimize oxidative damage. Primary
human CD34þ cells (IU Simon Cancer Center Angio BioCore)
were incubated at 37C in 5% CO2/5% O2 in Iscove’s modified
Dulbecco’s medium (IMDM) with 20% FBS, 1% pen-strep, 100
ng/mL stem cell factor (SCF), 100 ng/mL thrombopoietin (TPO),
and 100 ng/mL fms-like tyrosine kinase 3 (FLT3).
Mice
All animal experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) at IU School of Medicine.
Fancc/ mice [29] were a gift from Dr. D. Wade Clapp (IU).
RBC micronucleation assays
Fifty microliters of blood was collected from the murine lateral
tail vein into EDTA-coated collection tubes containing methanol
(2 mL, prechilled at 80C for O1 hour) and stored in 80C.
Next, 10 mL phosphate-buffered saline (PBS) was added, and
cells were pelleted at 600g (5 min, 4C). The supernatant was
aspirated, and red blood cells (RBCs) were resuspended in resid-
ual methanol/PBS. Twenty-microliter aliquots were transferred to
flow tubes and incubated in the dark with 90 mL of fluorescein iso-
thiocyanate (FITC)-conjugated anti-mouse CD71 (Biolegend) þ 1
mg/mL RNase A (Roche), first for 30 min at room temperature(RT) and then for 30 min on ice. Propidium iodide (Invitrogen)
staining at 1.25 mg/mL was followed by flow cytometry on a Facs-
Calibur machine (Becton-Dickinson). At least 500,000 events/
sample were acquired. A Hemavet 950FS (Drew Scientific) was
used for blood counts.
Deconvolution and super-resolution microscopy
Cells grown on ultrafine glass coverslips (Fisher) were fixed with
4% paraformaldehyde/PBS for 15 min (RT), PBS-washed,
permeabilized with 0.1% Triton X-100/PBS for 10 min,
PBS-washed, blocked in 5% bovine serum albumin (BSA)/PBS
or ImageIT SignalEnhancer (Life Technologies) for 1 hour, and
then incubated in primary antibody in 1% BSA/PBS overnight
(4C) or 2 hours (RT). Antibodies are listed in the Supplementary
Methods (online only, available at www.exphem.org). Next, cells
were PBS-washed and incubated with secondary antibodies
(1:2,000, 1% BSA/PBS) for 30 min (RT), PBS-washed, counter-
stained with Hoechst-33342 (Life Technologies) in PBS
(1:10,000) for 10 min, washed, and mounted in SlowFade Anti-
fade (Life Technologies).
For deconvolution microscopy, image stacks (z-section distance:
0.2 mm) were acquired on a Deltavision PersonalDx microscope
(Applied Precision) with a CCD camera using 20, 60, or
100 lenses and deconvolved using Softworx. Super-resolution
structured illumination microscopy (SR-SIM) images were acquired
on a Zeiss ELYRA PS.1 system with a CCD camera and 60/100
lenses, and processed via SIM/channel-alignment algorithms (Zen-
2011; Zeiss). Line-intensity profiles were quantified using Imaris
(Bitplane). z Sections on figures were exported using Imaris.
Images of FA patient marrow aspirates, marrow aspirates of pa-
tients diagnosed with immune-mediated aplastic anemia with
negative chromosome breakage test results, marrow cytospins,
and peripheral smears were obtained on a Zeiss Axiolab micro-
scope with Axiocam-105 color camera.
Cytokinesis-block micronucleus assays
Fibroblasts and MEFs grown on coverslips were treated with cyto-
chalasin B (2 mg/mL) for 24 hours, followed by processing/imag-
ing as described above; anti-CENPA immunofluorescence
visualized endogenous kinetochores. For drug treatments, cells
were exposed to 1 nmol/L taxol or MMC for 9 days before cyto-
chalasin B for 24 hours. A micronucleus was defined based on the
following criteria: (i) the diameter of the micronucleus must be
less than half that of the main nucleus, and (ii) the nuclear bound-
ary must be identified between the micronucleus and the nucleus.
The presence of kinetochores was determined based on visualiza-
tion of CENPAþ foci within the stack of z sections spanning the
entire micronucleus.
For CD34þ experiments, primary human CD34þ cells trans-
duced with green fluorescent protein (GFP)-tagged lentiviral
shRNA constructs were cultured for 5 days, sorted on a SORPAria
FACS system, attached to coverslips via cytospin (450 rpm, 7 min),
and analyzed in immunofluorescence assays as described above.
Mitotic spindle assembly assay
Culture plates with live fibroblasts on coverslips were removed from
the 37C incubator to replace growth medium with prechilled me-
dium and kept at 4C (1 hour). Next, the cold medium was replaced
with prewarmed medium (37C), and cells were returned to 37C
(15 sec) and immediately fixed (4% paraformaldehyde/PBS). On
1033Z. Abdul-Sater et al./ Experimental Hematology 2015;43:1031–1046staining with anti-pericentrin and anti-a-tubulin, cells were imaged
via deconvolution microscopy. Imaris (Bitplane) was used to mea-
sure length of microtubules in z sections and count centrosome-
associated microtubules within stacks.
Statistics
Statistical analyses were performed using GraphPad Prism 6. A
p value ! 0.05 was considered to indicate significance.
Study approval
Patients had been enrolled on the institutional review board-
approved protocol at IU School of Medicine (IRB No.
1108006474). All animal experiments were approved by the Insti-
tutional Animal Care and Use Committee (IACUC) at IU School
of Medicine.Results
In vivo error-prone mitosis during FA/ hematopoiesis
Mitotic failure was reported in FA cells ex vivo, and cyto-
kinesis failure was documented in FA marrows [17,23].
However, the in vivo evidence of abnormal early mitosis
in hematopoietic cells of FA patients has been missing.
To examine whether loss of FANCA (the gene most
commonly disrupted in FA [5]) predisposes hematopoietic
cells to erratic divisions in vivo, we quantified mitotic er-
rors in marrow aspirates of two FANCA/ patients with
pancytopenia but no MDS/AML. Consistent with the role
of FANCA in cell division, we observed an increased fre-
quency of abnormal mitotic figures in FANCA/ marrows
compared with marrow aspirates of patients diagnosed with
immune-mediated aplastic anemia after excluding FA by
negative chromosome breakage tests (p 5 0.01)
(Fig. 1A). Lack of chromosome congression leading to lag-
ging chromosomes in anaphase and micronucleation at
mitotic exit reflects weakened SAC or merotelic attachment
caused by centrosome malfunction [17]. The DNA bridges
in late mitosis may reflect impaired resolution of ultrafine
anaphase bridges [21]. Interphase nuclear morphology in
the erythroid lineage provided further evidence of in vivo
mitotic abnormalities (Fig. 1B, C). Erythroblast micronu-
cleation (Fig. 1B) suggests failure to segregate chromo-
somes into the daughter nuclei. The presence of bizarre
erythroblasts with multilobed nuclei (Fig. 1B) is consistent
with impaired chromosome segregation caused by erro-
neous SAC followed by cytokinesis failure [17,23]. Binu-
cleated erythroblasts (Fig. 1B) reflect lack of cytokinesis
after normal chromosome division [23]. These results pro-
vide quantitative in vivo evidence that abnormal mitoses
occur with increased frequency in the hematopoietic cells
of FANCA/ patients before development of MDS/AML.
We next validated these findings in a different in vivo
experimental system. We examined hematopoietic chromo-
somal instability in living Fancc/ mice using an in vivo
erythrocyte micronucleation assay [30,31]. This assay isbased on the notion that genomically unstable orthochro-
matic erythroblasts fail to extrude micronuclei, producing
micronucleated RBCs. Indeed, we observed micronucleated
RBCs in FA patients’ marrows (Fig. 1C). These micro-
nucleated RBCs are identified via flow cytometry as
DNA-containing CD71– RBCs (Fig. 1D). Three-month
old Fancc/ mice released almost threefold more micro-
nucleated mature RBCs into the peripheral blood than did
age-matched controls (p! 0.0001) (Fig. 1D). Importantly,
blood counts revealed no differences between the age-
matched wild-type and Fancc/ mice (Supplementary
Table E1, online only, available at www.exphem.org).
Thus, disruption of two different FA core genes (FANCA
and Fancc) leads to chromosomal instability during
in vivo hematopoiesis in humans and mice before the onset
of clinically significant BMF, myelodysplasia or leukemia.
A combination of interphase and mitotic errors drives
genomic instability in FA
As BMF and hematopoietic malignancies are consistent
clinical hallmarks of FA [1,5], we quantified the contribu-
tion of interphase and mitotic abnormalities to genomic
instability in FANCA-deficient hematopoietic cells. A
modified micronucleus assay (Fig. 2A) [32] allowed us to
determine the origin of multinucleation in primary human
CD34þ hematopoietic cells transduced with an shRNA
against FANCA [17], compared with control CD34þ cells.
We validated the FANCA shRNA in human CD34þ cells
(Fig. 2B, C). Upon FANCA knockdown, CD34þ cells
were immunostained for endogenous CENPA (a kineto-
chore marker [33]) and imaged by deconvolution micro-
scopy to classify cells based on the presence of CENPAþ
foci. As described [32], additional kinetochore-positive
nuclei arise through whole-chromosome missegregation in
mitosis, and supernumerary kinetochore-negative nuclei
result from DNA fragmentation (Fig. 2A). FANCA-
knockdown CD34þ cells developed higher multinucleation
because of both chromosome breakage (p 5 0.0083) and
faulty chromosome segregation (p 5 0.0001), compared
with control CD34þ cells (Fig. 2D, E). We concluded
that silencing FANCA impairs both interphase and mitotic
genome maintenance in human hematopoietic cells.
To validate this finding in primary FA-deficient patient
cells and eliminate the possibility of nonspecific shRNA-
induced phenotype [34], we pursued cytokinesis-block
cytome assays [32]. Dividing cells are treated with
cytochalasin B (a cytokinesis inhibitor) prior to CENPA
immunofluorescence. Inhibition of cytokinesis generates
binucleated cells on error-free chromosome partition, and
the presence of micronuclei indicates abnormal chromo-
some segregation during the last mitosis. Again, CENPA
positivity distinguishes mitotic-failure micronuclei from
DNA-breakage micronuclei (Fig. 3A) [35].
FANCA/ fibroblasts had an increased frequency
of both chromosome missegregation (p 5 0.0391) and
Figure 1. In vivo chromosomal instability and abnormal mitoses during human FANCA–/– and murine Fancc–/– hematopoiesis. (A) Representative
abnormal mitoses in FANCA–/– patient bone marrow aspirates. Quantification (upper right) represents data from two different FA patients and two non-
FA patients (96 mitoses in non-FA and 73 mitoses in FA; Fisher’s exact test). Bar 5 5 mm. (B) Examples of abnormal interphase nuclear morphology in
FANCA–/– patients’ hematopoietic cells that have undergone aberrant mitoses compared with a normal non-FA interphase erythroblast. Bar 5 5 mm. (C)
Micronucleation of FANCA–/– bone marrow erythroblasts, reticulocytes, and mature red blood cells (top) and Fancc–/– murine RBCs in peripheral blood
(bottom). Bars 5 5 mm (top) and 2 mm (bottom). (D) Increased frequency of CD71–, PIþ micronucleated mature RBCs in peripheral blood of 3-month-
old Fancc–/–mice. (E) Quantification of micronucleated RBCs identified by flow cytometry is shown as fold change relative to wild-type levels. Bars indicate
means 6 SEM;O10 age-matched mice/genotype from multiple independent experiments were analyzed using Student’s t test. All specimens were imaged
with a Zeiss Axiolab system equipped with an Axiocam 105 color camera.
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gene-corrected cells (Fig. 3B, C). Similarly, Fancc/
MEFs had an increased incidence of micronucleation
resulting from both chromosome breakage (p 5 0.0004)and chromosome missegregation (p 5 0.0078) compared
with wild-type MEFs (Fig. 3D, E). Thus, disruption of FA
signaling impairs interphase and mitotic fidelity not only
during hematopoiesis (Fig. 2), but also in fibroblasts and
Figure 2. FANCA maintains genomic integrity during interphase and mitosis in primary human CD34þ cells. (A) Assay schematic. Kinetochore/centrosome
immunofluorescence staining distinguishes multinucleation generated through whole-chromosome missegregation from multinucleation resulting from DNA
breakage. (B) FANCA shRNA efficiently knocks down FANCA protein in primary human CD34þ cells. b-Actin serves as loading control. (C) Functional
validation of FANCA shRNA in primary human CD34þ cells. FANCA shRNA renders CD34þ cells hypersensitive to mitomycin C as compared with CD34þ
cells transduced with control shRNA. Error bars represent means 6 SEM. Significance was determined using a two-way analysis of variance with Sidak
correction. (D) Representative images of multinucleation resulting from FANCA knockdown in human CD34þ cells. Regions of interests are marked in
red or yellow and enlarged on the right. Green arrow points to a CENPA-positive centromere/kinetochore within the supernumerary nucleus. Bars 5 2
mm (left) and 1 mm (right) (E) Quantification of multinucleation resulting from weakened SAC or chromosome breakage in control and FANCA-
knockdown CD34þ cells. At least 500 cells per group were counted. Results were analyzed using Student’s t test and represented as means 6 SEM.
1035Z. Abdul-Sater et al./ Experimental Hematology 2015;43:1031–1046MEFs (Fig. 3). These findings suggest that multiple
FA/BRCA proteins may play evolutionarily conserved roles
in mitotic genome housekeeping.
FANCA regulates centrosome-mediated spindle
microtubule assembly in early mitosis
We and others have reported defects in centrosome ampli-
fication in cells lacking the FA/BRCA pathway [16–19],
but the impact of FA signaling on mitotic centrosome func-
tion per se has not been studied. At mitotic entry, maturing
centrosomes nucleate microtubules to build the mitotic
spindle [36]. These microtubules undergo controlled rear-
rangements to properly capture kinetochores beforeanaphase begins [37]. Because FANCA localizes to the
mitotic apparatus [16,17], and FA signaling is implicated
in the SAC [17], we wondered whether FANCA regulates
the dynamic equilibrium of spindle microtubule assembly
in early mitosis. We quantified the ability of primary
patient-derived FANCA/ and FANCAþ fibroblasts to
establish spindles in modified spindle assembly assays
(Fig. 4A) [38]. Live cells were first placed at 4C to desta-
bilize microtubules (Fig. 4B) and then given prewarmed
growth medium to stimulate spindle regrowth, fixed, and
analyzed via quantitative deconvolution microscopy. Prom-
etaphase FANCA/ centrosomes demonstrated impaired
spindle nucleating ability evidenced by the decreased
Figure 3. Micronucleation on loss of FA signaling results from a combination of interphase and mitotic errors. (A) Schematic of the cytokinesis-block micro-
nucleus test, which discriminates the origin of aneuploidy based on the presence or absence of kinetochores within micronuclei. (B) Representative images of
micronuclei in FANCA–/– primary patient fibroblasts. Bars 5 10 mm (left) and 2 mm (right). (C) Quantification of micronuclei resulting from whole-
chromosome missegregation versus chromosome breakage in primary FANCA–/– and FANCAþ fibroblasts. Error bars represent means 6 SEM. (D) Repre-
sentative images of micronuclei in Fancc–/– MEFs. Scale bars 5 10 mm (left) and 2 mm (right). (E) Quantification of micronucleation resulting from
chromosome missegregation and chromosome breakage in wild-type and Fancc –/– MEFs. At least 260 cells were counted per condition; significance
was determined with Student’s t test. Cells were imaged with deconvolution microscopy (Applied Precision PersonalDx) and deconvolved with Softworx
imaging suite (10 iterations, ratio: conservative).
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Figure 4. Loss of FANCA disrupts spindle microtubule assembly at prometaphase centrosomes. (A) Experiment design. Microtubules of living FANCA–/–
and FANCAþ cells were destabilized by cold treatment (4C for 1 hour). Cells were then returned to 37C to initiate microtubule reassembly and fixed with
4% paraformaldehyde 15 sec later. (B) Cold treatment fully destabilizes microtubules in FANCAþ and FANCA–/– prometaphase cells. (C) Representative
images of mitotic spindle assembly in FANCAþ and FANCA–/– prometaphase cells stained with anti-a-tubulin (green) and anti-pericentrin (red) antibodies.
Images were captured with 60 lens on the Deltavision deconvolution microscope. Scale bars 5 2 mm (left and right) and 500 nm (region of interest in
center). (D, E) Quantification of spindle microtubules per centrosome (D) and microtubule length (mm) (E) in gene-corrected and FANCA–/– cells treated
as described in (A). Data represent two independent experiments (n 5 130 microtubules/experiment), and error bars represent SEM. (F) Representative
mitotic HeLa cells stained with anti-FANCA (red) and anti-a-tubulin (green) antibodies, imaged on an ELYRA PS.1 super-resolution microscope using
SIM technology. Inset: Enlarged centrosome-containing region of interest. White dashed line represents the line of fluorescence intensity profile. Bar 5 2
mm. Cells were imaged with deconvolution microscopy (Applied Precision PersonalDx) and deconvolved with Softworx imaging suite (10 iterations, ratio:
conservative). (G) Fluorescence intensity profiles of FANCA (red) and a-tubulin (green) signal.
1037Z. Abdul-Sater et al./ Experimental Hematology 2015;43:1031–1046
1038 Z. Abdul-Sater et al./ Experimental Hematology 2015;43:1031–1046number of microtubules emanating from each centrosome
(p # 0.0001) (Fig. 4C, D). The spindle microtubules nucle-
ated by FANCA/ centrosomes were shorter (p# 0.0001)
(Fig. 4E) than microtubules assembled in gene-corrected
cells. Importantly, FANCA/ cells containing supernu-
merary centrosomes [16,17] were excluded from the anal-
ysis. Therefore, FANCA is essential not only for the
maintenance of centrosome number, but also for efficient
mitotic spindle assembly. Super-resolution structured illu-
mination microscopy (SR-SIM) revealed endogenous
FANCA on mitotic centrosomes in close proximity to spin-
dle microtubules (Fig. 4F, G), consistent with the role of
FANCA in spindle dynamics.
FANCA shuttles to the pericentriolar material during
mitotic centrosome maturation
Multiple FA proteins, including FANCA (Fig. 4F, G),
localize to centrosomes and mitotic spindles [16–18]. How-
ever, it is unknown whether FANCA association with cen-
trosomes changes between interphase and mitosis, as
expected of a bona fide regulator of mitotic centrosome/
spindle function [39,40].
Centrosome maturation prepares centrosomes for
mitosis through reorganization of the pericentriolar mate-
rial (PCM). A phosphosignaling circuit of cyclin-
dependent kinases (CDKs), polo-like kinase 1 (PLK1),
and Aurora A [41] recruits pericentrin [39] and g-tubulin
[40] to the PCM at mitotic entry to increase the spindle
nucleating centrosome activity [42]. Because FANCA reg-
ulates spindle assembly (Fig. 4B–E), we wondered whether
FANCA is recruited to the PCM of maturing centrosomes
similar to these other centrosome-spindle regulators.
To examine FANCA subcentrosomal localization, we
employed deconvolution and super-resolution microscopy,
which allows visualization of centrosomes beyond the
diffraction limit imposed by conventional microscopes
[43,44]. At mitotic entry, FANCA shuttled from centrioles
toward the PCM and colocalized with pericentrin,
g-tubulin, and the minus end of spindle microtubules until
the mitotic exit (Fig. 5A, B; Supplementary Figures E2–E5,
online only, available at www.exphem.org). In interphase,
FANCA returned to the mother centriole (Supplementary
Figure E6, online only, available at www.exphem.org).
These observations were confirmed with multiple primary
antibodies and imaging of FANCA/ patient cells stably
expressing GFP-FANCA.
To thoroughly analyze FANCA distribution within the
PCM, we analyzed individual 84-nm-thin super-resolution
sections of mitotic centrosomes. At the mid-centrosome
level, we observed well-organized FANCA fibers extending
through and beyond the pericentrin-decorated PCM
network from centrioles toward microtubule nucleation
sites (Fig. 5B, C). This dynamic relocalization of FANCA
to the PCM during mitosis supports the newly discovered
role of FANCA in spindle microtubule nucleation (Fig. 4).Loss of FANCA allows escape from SAC arrest and
apoptosis
The FA/BRCA pathway repairs interphase DNA damage
[45,46] and participates in the SAC [17]. To examine the
fate of FANCA-deficient cells on SAC activation, we em-
ployed time-lapse imaging of primary FANCA/ and
gene-corrected cells treated with taxol, a microtubule-
stabilizing chemotherapeutic agent (Fig. 6A). As described
in other cells [47,48], FANCA-corrected, taxol-exposed
cells entered prolonged prometaphase arrest followed by
cell death without exiting mitosis. FANCA/ cells were
more likely to escape taxol-induced SAC arrest and
generate multinucleated interphase-like cells (p 5 0.0215)
(Fig. 6B–E). These findings validate the role of FANCA
in the SAC and indicate that loss of FANCA facilitates the
escape of chromosomally unstable cells from mitotic death
caused by unsatisfied SAC [47].
FANCA/ cells are hypersensitive to taxol
A significant fraction of multinucleated cells that escape
taxol-induced arrest [49] or form on failed mitosis [50,51]
are physiologically eliminated to prevent genomic insta-
bility [26,52]. Complete SAC disruption causes chromo-
somal instability incompatible with cell survival [53].
Thus, we hypothesized that loss of FANCA may render cells
hypersensitive to taxol.
As previous studies evaluating response of FA/
cells to anti-mitotic chemotherapeutic agents generated
conflicting data [16,54], we performed rigorous dose–
response experiments to thoroughly examine this concept.
We found that two separate FANCA/ primary patient
cell lines harboring different FANCA mutations are hy-
persensitive to taxol; stable FANCA expression rescued
taxol hypersensitivity in both lines in two independent
cell viability assays (Fig. 6F–H; Supplementary Figures
E7 and E8, online only, available at www.exphem.org).
Likewise, FANCC/ primary fibroblasts displayed taxol
hypersensitivity compared with FANCC-corrected cells
(Supplementary Figure E8C). As expected [1,5],
FANCA/ and FANCC/ cells exhibited decreased
survival on exposure to the crosslinking agent MMC
(Fig. 6F–H; Supplementary Figure E9, online only, avail-
able at www.exphem.org). These findings, together with
previously published work [16], indicate that loss of
FANCA or FANCC is synthetically lethal with exposure
to anti-mitotic chemotherapeutic agents.
Chemotherapy-exposed FANCA/ cells develop
distinct patterns of genomic instability because of
separate interphase and mitotic checkpoint
abnormalities
Having established the hypersensitivity of FA/ cells to
interphase DNA crosslinkers and anti-mitotic agents, we
wanted to understand how loss of FANCA confers hyper-
sensitivity to these separate classes of chemotherapeutics.
Figure 5. FANCA shuttles to the pericentriolar material during mitosis. (A) HeLa cells were immunostained with antibodies against endogenous FANCA
(red) and centrin (green), imaged with deconvolution microscopy (Applied Precision PersonalDx) and deconvolved with Softworx imaging suite (10 itera-
tions, ratio: conservative). Fluorescence intensity profiles indicate that FANCA co-localizes with centrin in interphase and migrates away from centrioles at
metaphase. Bars 5 1.5 mm (left) and 300 nm (right). (B) Representative super-resolution image of human fibroblast stably expressing GFP-FANCA and
stained with antibody against the pericentriolar material marker (pericentrin). Inset: Three-dimensional rendering of the centrosome reveals co-
localization of GFP-FANCA and pericentrin. Bar 5 2 mm. The yellow region of interest is magnified (C) to show FANCA fibers embedded within the
PCM (centrosome cross section) and extending toward the spindle (centrosome outer layer section). Fluorescence intensity profiles of GFP-FANCA/
pericentrin signal at PCM and spindle are on the right. Bar 5 500 nm. SR-SIM images were acquired on a Zeiss ELYRA PS.1 super-resolution microscopy
system and exported using the Imaris imaging suite.
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Figure 6. Loss of FANCA promotes escape from SAC and is synthetic lethal with low-dose taxol exposure. (A) Assay schematic. Prolonged activation of
SAC triggers cell death to prevent genomic instability by eliminating cells that cannot satisfy the checkpoint. Escape from SAC followed by erratic chro-
mosome segregation and mitotic exit generates multinucleated cells. (B) Representative time-lapse imaging snapshots of FANCAþ and FANCA–/– cells
exposed to taxol. Note prolonged SAC arrest followed by cell death in gene-corrected cell and escape for SAC followed by cytokinesis failure and multi-
nucleation in FANCA–/– cell. Bar 5 15 mm. Time from mitotic entry is shown for each frame. Time-lapse phase-contrast frames of cells grown in DMSO
supplemented with 10% FBS at 37C, 5% CO2 were acquired every 2 min for at least 24 hours on a Nikon Biostation live-imaging system (C, D) Quan-
tification of time-lapse imaging experiments. FANCA–/– cells are more likely to escape SAC and less likely to be eliminated through SAC-associated death
compared with gene-corrected isogenic cells (p 5 0.0215). Data for 115 mitotic FANCAþ cells and 129 mitotic FANCA–/– cells (three experimental rep-
licates for each cell line) were analyzed with a two-tailed t test (Supplementary Videos 1 and 2, online only, available at www.exphem.org). (E) Prolonged
prometaphase arrest in FANCAþ cells and multinucleation in FANCA–/– cells on 24-hour exposure to taxol in an independent experiment. Images acquired
on an Applied Precision PersonalDx deconvolution microscope.
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instability in primary FANCA/ and gene-corrected cells
at baseline (Supplementary Figure E10, online only, avail-
able at www.exphem.org) and upon treatment with suble-
thal doses of MMC and taxol. We selected drug doses
that decreased growth of FANCA/ cells compared withisogenic FANCAþ cells without fully arresting FANCA/
 cells or inducing cell death evidenced by increased
sub-G1 fraction on flow cytometry (Fig. 7A and not
shown).
Prolonged treatment with 1 nmol/LMMC reduced growth
of FANCA/ cells as a result of persistent activation of the
Figure 6. (continued) (F) Representative colony-forming unit (CFU) assay plates. Primary FANCA–/– fibroblasts and FANCAþ fibroblasts (500 cells per 10-
cm2 plate) were exposed to taxol for 11 days. Note decreased colony formation on FANCA–/– plates exposed to 1 nmol/L taxol. (G) Quantification of the
CFU assay in (F). FANCA–/– cells are more sensitive to 1 nmol/L taxol than FANCAþ cells in the CFU assay. MMC at 1 nmol/L was used as positive control.
(H) Direct cell counts confirm that stable expression of FANCA rescues both taxol and MMC hypersensitivity of FANCA–/– patient cells. Two-way analysis
of variance with Sidak correction was used for data comparison. Data represent pooled results of three separate experiments, expressed as means 6 SEM in
triplicates.
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replication (p ! 0.0001) and decreased G1 fraction
(p 5 0.0029) (Fig. 7A–D). This observation is consistent
with the exaggerated MMC-induced G2/M arrest of FA cells
caused by DDR failure [45,46]. In further support of this
notion, exposure to low-dose MMC increased multinuclea-
tion resulting fromDNA breakage (p5 0.0223), but not chro-
mosome missegregation (Fig. 7E–G). Sublethal taxol
exposure affected FANCA/ cells differently. Prolonged
treatment with low-dose taxol (but not MMC) significantly
decreased the mitotic fraction of FANCA/ cells compared
with gene-corrected cells (p! 0.0001) (Fig. 7H, I), consistent
with impaired SAC (Fig. 6). Furthermore, low-dose taxol
increased multinucleation of FANCA/ patient cells sec-
ondary to mitotic chromosome missegregation (p !
0.0001) as well as chromosome breakage (p 5 0.0059)
(Fig. 7J, K). Interestingly, multinucleated cells continued
to enter S phase (Supplementary Figure E11, online only,
available at www.exphem.org) [52,55].
In summary, these results (i) provide evidence that both
impaired DDR and error-prone mitosis contribute to chro-
mosomal instability in FANCA/ cells in vivo and
ex vivo, (ii) offer insights into the role of the FA pathway
in the response to DNA-crosslinking agents and anti-
mitotic chemotherapeutic agents, and (iii) open potential
new inroads toward synthetic lethal chemotherapy against
FA-deficient cancers.Discussion
Disrupted FA/BRCA signaling causes genomic instability
and cancer. The FA/BRCA tumor suppressor network
orchestrates interphase DDR and DNA replication [1,5].
Multiple lines of evidence have implicated FA/BRCA
signaling in centrosome maintenance and mitotic check-
points [16–19,21,23], but the in vivo importance of thesefindings is unknown. We found that both abnormal inter-
phase and error-prone mitosis significantly contribute to
the in vivo hematopoietic genomic instability in FA/ hu-
mans and mice, suggesting a role for the FA/BRCA network
in genome surveillance throughout the cell cycle (Fig. 7L).
FANCA/ patients’ hematopoiesis is afflicted by
mitotic errors. Lagging chromosomes caused by an
in vivo SAC impairment [17] and persistent anaphase/telo-
phase bridges [21,22] occur with increased frequency in
FANCA/ patients (Fig. 1). In agreement with the work
from the D’Andrea group [23], binucleated hematopoietic
cells (Fig. 1) are signs of faulty cytokinesis. Increased chro-
mosome missegregation during erythropoiesis in Fancc/
mice (Fig. 1D, E) indicates that other FA/BRCA proteins
are essential for in vivo high-fidelity chromosome partition
in hematopoietic cells in an evolutionarily conserved
manner. The onset of FA-associated mitotic abnormalities
precedes the MDS/AML (Fig. 1, Supplementary Table
E1), suggesting that impaired mitosis may contribute to
carcinogenesis in FA. Indeed, FISH analysis detected chro-
mosomally unstable clones in 15% of FA patients with
morphologically normal marrows [56], and gross chromo-
somal instability is a hallmark of MDS/AML in FA [57].
More research is needed to quantify the impact of
haphazard mitosis on FA-associated myelodysplasia and
cancer.
The irregular mitosis during FA/ hematopoiesis is a
consistent but relatively rare event (Figs. 1, 2). Further,
although multinucleated cells with centrosome clusters are
easily seen in FA-deficient cancer cells [17], multinucleation
in FA/ primary cells is more subtle (Figs. 2, 3) [17],
perhaps because cancers cannot eliminate misdividing cells
through backup checkpoints. Indeed, centrosome abnormal-
ities induce TP53-dependent cell cycle arrest [51] and
apoptosis [50], and activation of TP53 contributes to BMF
in FA [58]. TP53 inactivation boosts hematopoiesis but
Figure 7. FANCA–/– cells exposed to genotoxic stressors develop genomic instability through a combination of interphase and mitotic checkpoint abnor-
malities. (A) Prolonged activation of the G2/M checkpoint in FANCA–/– cells grown in low-dose MMC for 9 days. (B) No difference in mitotic cell fraction
between MMC-treated FANCA–/– and FANCAþ cells indicates that the increased FANCA–/– G2/M fraction in (A) reflects G2 arrest prior to mitotic entry. (C,
D) DNA replication arrest in FANCA–/– cells exposed to 1 nmol/L MMC is rescued by FANCA gene correction. S-Phase cells were labeled red by EdU
incorporation. (E–G) Increased multinucleation caused by DNA breakage, but not chromosome missegregation, in FANCA–/– cells grown in low-dose
MMC. (H, I) Flow cytometry reveals a decreased fraction of mitotic cells in FANCA–/– cells exposed to sublethal dose of taxol.
1042 Z. Abdul-Sater et al./ Experimental Hematology 2015;43:1031–1046promotes MDS/AML in FA [59], and AML with bizarre
karyotype instability occurred in an FA patient with somatic
loss of heterozygosity of the TP53-harboring region of
chromosome 17 [60]. Thus, aneuploidy and centrosome
disruption on inactivation of FA/BRCA signaling may
trigger TP53-dependent checkpoints to limit the risk of
leukemia at the cost of BMF.
The role of FANCA in mitosis is not clearly defined.
Impaired FA signaling promotes accumulation ofcentrosomes as a result of DDR-induced centrosome over-
replication [18,19] and deregulated mitosis [17,23]. Super-
numerary centrosomes promote chromosomal instability
through multiple mechanisms [26,61]. We found that
FANCA regulates centrosome-associated spindle assembly
(Fig. 4), and FANCA shuttles from centrioles to the PCM
spindle attachment sites at mitotic entry (Figs. 4 and 5).
Dissecting FANCA-dependent mitotic centrosome–microtu-
bule–kinetochore interactions in more detail will help
Figure 7. (continued) (J, K) Treatment with taxol increases chromosome segregation errors and chromosome breakage in FANCA–/– cells. (L) Compound
interphase and mitotic origins of genomic instability in FA-deficient cells (see text for discussion). Exponential accumulation of DNA damage may result in
activation of cell cycle arrest/apoptosis (bone marrow failure) or malignant transformation (leukemia and solid tumors). All flow cytometry data represent
pooled three replicates for each cell line and condition compared with two-tailed t test. EdU incorporation counts were compared via two-way analysis of
variance with Sidak’s multiple comparison test.
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esize that functional and numerical centrosome abnormal-
ities in FA-deficient cells may further promote
chromosomal instability by promoting merotelic kineto-
chore attachment to spindle microtubules; this mechanism
of genomic instability has been elucidated in non-FA cells
acquiring supernumerary centrosomes [61,62]. Interestingly,
FANCA is phosphorylated by NIMA-related kinase 2
(NEK2) [16] and AKT kinase [63]; FANCJ and FANCD1
may regulate polo-like kinase 1 (PLK1) [18,19], which is
essential for spindle function [64]; and FANCC binds the
key mitotic cyclin-dependent kinase 1 (CDK1) [65], which
coimmunoprecipitates with the FA core complex [66].More-
over, loss of FANCA is synthetic lethal with PLK1 knock-
down [67], and CDK inhibitors disrupt ionizing radiation-
induced formation of FANCD2 foci [68]. Future work will
examine these pathway connections to evaluate their transla-
tional relevance in cancer and FA.
We found that loss of FA signaling is synthetically lethal
with taxol exposure, highlighting the role of FA-dependent
SAC in cell survival. Kim et al. observed hypersensitivity
of FANCA-knockdown cells to nocodazole [16]. Taxol
and nocodazole are mechanistically different [69]: nocoda-
zole disrupts spindle–kinetochore attachment, whereas
taxol renders the attached microtubules unable to stretch
the kinetochores. Because the FA pathway is essential for
taxol- and nocodazole-induced SAC [17], FANCA may
regulate SAC by intra-kinetochore tension.
Of note, others have found that FANCG/FANCC-deficient
pancreatic cancer cells exposed to taxol accumulate DNA at
a rate similar to that of gene-corrected cells in in vitro fluo-
rescence assays [54], and concluded that FA/ cells are
not hypersensitive to anti-mitotic agents. However, FA/
cells multinucleate (Fig. 6) [16,17] and replicate
(Supplementary Figure E11, online only, available at
www.exphem.org) on exposure to anti-mitotic agents, sug-
gesting why cell growth assays quantify taxol responsewith better specificity than total DNA measurements. Inter-
estingly, low-dose taxol promotes chromosome missegrega-
tion and DNA breaks in FANCA/ cells. Consistent with
this notion, the Pellman group demonstrated that micronu-
clei produced by mitotic errors undergo excessive mutagen-
esis [52] with secondary chromosome breakage [55] caused
by erratic replication. The micronucleus-associated chromo-
some breakage may be further exacerbated by failed DDR in
FANCA/ micronuclei.
Micronucleation has been noted in FA for decades
[70,71], but it was unclear whether it reflects interphase ab-
normalities or erratic mitoses. We addressed this question
with quantitative high-resolution imaging-based micronu-
cleation assays validated in previous studies [32]. Given
the key role of FA signaling in interphase [1,5], we made
an effort to confirm that kinetochore-containing micronu-
clei are not produced simply by impaired DDR. Impor-
tantly, the DNA-crosslinking agent (MMC) produced
‘‘DNA breakage’’ micronuclei, but not ‘‘chromosome
missegregation’’ micronuclei (Fig. 7F, G), confirming the
assay’s specificity and sensitivity in distinguishing inter-
phase from mitotic errors. Thus, we concluded that
genomic instability results from DNA breakage and chro-
mosome missegregation in multiple FA/ hematopoietic
and nonhematopoietic cell types (Figs. 2 and 3). On the
basis of these and other findings [17], we propose that
FANCA deficiency causes genomic instability through a
dual mechanism of impaired interphase DDR/replication
and defective mitosis [72] (Fig. 7L). This model explains
the FA-associated patterns of genetic instability and hyper-
sensitivity to both DNA-crosslinking and anti-mitotic
agents. Interphase errors exacerbate mitotic abnormalities,
and mitotic failure promotes interphase mutagenesis.
Chromatid remnants generated through impaired DDR or
replication are randomly segregated in mitosis. Defective
midbody constriction [25] and cytokinesis [23] may shatter
lagging chromosomes resulting from impaired SAC [17,73]
1044 Z. Abdul-Sater et al./ Experimental Hematology 2015;43:1031–1046and break unresolved anaphase bridges [21,22]. After
mitotic exit, cells may attempt to repair splintered DNA
through chromothripsis, the mutagenic process of randomly
reconnecting chromosome fragments via non-homologous
end joining (NHEJ) [74–76]. Because FA/ cells favor
error-prone NHEJ over homologous recombination [77],
chromothripsis may have a particularly detrimental impact
on genomic stability on loss of the FA/BRCA network.
Our observations unveil the translational importance of
mitotic defects caused by loss of FA/BRCA signaling. So-
matic disruption of FA/BRCA genes occurs in malignancies
in non-FA patients, including leukemia [12,13,78,79] and
cervical [10], ovarian [11,80,81], breast [82], bladder [83],
and lung [84] cancers. Our analysis of the COSMIC [85]
database revealed multiple cancer-associated FANCA and
FANCC-inactivating mutations in non-FA patients
(Supplementary Figure E12, online only, available at
www.exphem.org). As FA/ cells are hypersensitive to
anti-mitotic agents, future preclinical studies will determine
whether targeting of mitosis can be employed in FA-
deficient cancers. This strategy may complement other
evidence-driven precision medicine efforts against FA/
cancers, such as targeting of PARP-dependent DNA repair
pathways [86–88], DNA damage kinases [89], and selective
use of crosslinkers [11,68].
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Supplementary methods
Immunoblotting
For detection of FANCA protein expression, CD34þ cells
were lysed in M-Per buffer (Thermo Scientific) containing
phosphatase and protease inhibitors (Roche), and protein
concentration was determined by BCA (Pierce). Fifteen mi-
crograms of protein was loaded per well in a 4%–12%
gradient Bis-Tris gel (Life Tech). Blots were blocked in
5% milk for 1 hour, then incubated overnight with anti-
FANCA antibody (ab5063, Abcam) diluted 1:2,000 in 5%
milk. Blots were washed with 0.1% Tween 20 in PBS
(PBS-T) and incubated with anti-rabbit IgG horseradish
peroxidase-linked secondary antibody diluted in PBS-T
and 0.5% milk. Signal was detected via the enhanced chem-
iluminescence system (Life Tech).
CD34þ CFU assay
Transduced CD34þ cells were grown in triplicate (2,500
cells/35 mm dish) in Methocult (H4434) methylcellulose-
based medium containing recombinant cytokines (Stem
Cell) and varying concentrations of MMC. Plates were
incubated at 37C, 5% O2 for 11 days. Colonies were
then counted and defined as clusters of O50 cells.
Flow cytometry
To detect functional correction of isogenic-corrected patient
fibroblasts, cells were treated for 48 hours with 33 nmol/L
MMC and then harvested on incubation with HyClone Hy-
QTase (Fisher) detachment solution for 15 min. Cells were
pelleted and resuspended dropwise in cold 70% ethanol and
stored at –20C overnight. The following day, cells were
spun down and resuspended in FxCycle PI/RNase Staining
Solution (Life Tech) for cell cycle analysis.
For quantification of mitotic cells, fibroblasts were
treated with 1 nmol/L MMC or 1 nmol/L taxol for 9
days. Cells were then removed from tissue culture plates
on incubation with HyClone HyQTase (Fisher) detachment
solution for 15 min at 37C followed by 4% paraformalde-
hyde/PBS fixation for 10 min. Cells were pelleted, resus-
pended in 90% methanol, and stored at –20C overnight.
The next day, cells were incubated in 0.5% BSA/PBS for
4 min, pelleted, and stained with an Alexa Fluor 488-
conjugated phospho-histone H3 antibody (Cell Signaling)
diluted 1:50 in 0.5% BSA/PBS for 1 hour in the dark.
The cells were next washed with PBS and analyzed on a
FacsCalibur flow cytometer (Becton-Dickinson). Flow
cytometry data analysis was performed using Flow Jo
software.
S-Phase quantification
Cells grown on coverslips were treated for 9 days with
1 nmol/L MMC or 1 nmol/L taxol as described above,
pulsed with EdU using the Click-iT EdU Imaging Kit
(Life Technologies) for 45 min, then fixed and stained
according to the manufacturer’s protocol. Nuclei were
counterstained with Hoechst 33342. Cells were imaged on
the Deltavision deconvolution microscope, and the fraction
of EdU-positive nuclei was manually quantified.
Generation of MEFs
To generateMEFs,Fanccþ/– animals were intercrossed, and
pregnant female mice from timed matings were sacrificed at
day E13.5-14.5. Individual embryos were removed from the
uterus, and then the tail and liver region of each embryowere
removed. The head was also removed for polymerase chain
reaction genotyping. Remaining embryo tissue was minced
using a sterile razor blade and incubated with 1 mL 0.25%
trypsin–EDTA (Life Technologies) for 10 min at 37C in a
10-cm tissue culture dish. Next, 2 mL of growth medium
was added, and the tissue was disaggregated into a single-
cell suspension by repeated passage through a 16-gauge nee-
dle attached to a 3-mL syringe (Becton Dickinson). Eight
milliliters of growth medium was then added to the plate,
and MEFs were further cultured as described above. For all
experiments, passage 2 MEFs were used.
Clonogenic (CFU) assays and direct cell count assays
Cells of the indicated genotypes were plated on 10-cm cell
culture dishes (500 cells/plate). MMC or taxol (purchased
from Sigma) was added to the growth medium 24 hours
later. Plates were cultured in a 5% oxygen incubator for
11 days, then fixed and stained with 0.4% methylene
blue–methanol to manually count colonies. A colony was
defined as $50 cells/group. Plates were scanned using an
Epson color scanner. For direct cell counting, six-well
plates were seeded with 1  105 cells/well and treated
with the indicated doses of MMC or taxol for 9 days.
Cell counts were performed using a hemocytometer.
Bioinformatics analysis of cancer-associated FA
mutations
Somatic cancer-associated mutations of FANCA and
FANCC were identified within the COSMIC database [1].
The functional impact of mutations was examined with Mu-
tation Assessor algorithm; mutations producing a functional
impact score (FIS) O1.938 were considered potentially
disruptive [2].
Live imaging
Cells were plated at 20,000 cells per quadrant in a 35-mm
Hi-Q4 (Ibidi) culture dish. After 2 days, taxol was added
(final concentration 5 200 nm), and time-lapse phase-
contrast images (5 z sections, total 5 10 mm) were acquired
every 2 min for a period of 48 hours using a BioStation IM-
Q time-lapse imaging system (Nikon) equipped with a 20
0.8 NA Plan Fluor objective lens. NIS-Elements AR Anal-
ysis 4.10.02 or NIS-Elements Viewer 4.20 microscope im-
aging software (Nikon) was used for video analysis. Videos
were exported via Imaris (Bitplane) and Adobe Photoshop.
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Antibodies used for immunofluorescence
The following primary antibodies were used in this study:
rabbit anti-CENPA (Cell Signaling, 1:200), mouse anti-a-
tubulin (Cell Signaling, 1:100), rabbit antipericentrin (Ab-
cam, 1:100), mouse anticentrin 3 (Santa Cruz, 1:100),
mouse anti-g-tubulin (Abcam, 1:100), rabbit anti-CEP170
(Abcam, 1:100), as well as rabbit anti-FANCA (Abcam).
Alexa 488- and Alexa 594-conjugated antibodies (Life
Technologies) were used for primary antibody detection.
Supplementary Video E1. Primary FANCA/ patient
cell escapes taxol-induced spindle checkpoint arrest and
exits mitosis to generate one giant multinucleated cell after
failed cytokinesis.
Supplementary Video E2. FANCA gene correction res-
cues the spindle assembly checkpoint in FA patient-derived
cell. Note prolonged taxol-induced mitotic arrest followed
by cell death.
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Supplementary Table E1. Fancc/ mice have normal peripheral
blood counts at 12 weeks of agea
Peripheral blood count
Wild type Fancc/ p Value
White blood
cells (K/mL)
16.26 6 1.285 18.19 6 1.069 0.2548
Hemoglobin (g/dL) 14.49 6 0.508 15.08 6 0.1863 0.2574
Platelets (K/mL) 1,053 6 70.96 1,111 6 62.97 0.5440
aNo erythroblasts or myeloblasts were noted on manual review of any
Fancc/ or wild-type mice at 3 months of age (n O 10 mice per geno-
type). Values are means 6 SEM of 15 animals/group. p Values were
obtained with an unpaired Student t test.
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Supplementary Figure E1. Functional validation of FANCA and FANCC isogenic gene correction of primary patient fibroblasts. Cell cycle flow profiles of
FANCA-deficient patient line MNHN (top), FANCA-deficient patient line RA885 (middle), and FANCC-deficient patient line WD-C1 (bottom). Primary
patient cells and their isogenic gene-corrected counterparts were either untreated or treated with MMC for 48 hours and analyzed for DNA content via
flow cytometry to determine functional FA correction [3,4]. Note partial correction of MMC-induced G2/M arrest in FANCA/ patient cells on correction
with wild-type FANCA and in FANCC/ patient cells transduced with wild-type FANCC.
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Supplementary Figure E2. FANCA localizes to the proximity of microtubule attachment sites on metaphase centrosomes. (A) Super-resolution image of a
metaphase HeLa cell co-stained with anti-FANCA (red) and anti-a-tubulin (green) antibodies. Hoechst 33342 (blue) was used to counterstain DNA. Bars5 3
mm. Regions of interest marked as yellow squares are magnified (B) to show FANCA localizing to the minus end of the spindle microtubules at centrosomes.
Bars 5 500 nm. Dotted white lines indicate the FANCA and tubulin fluorescence intensity profiles provided in (C).
Supplementary Figure E3. FANCA-GFP is found at the minus ends of microtubules during metaphase. (A) Representative primary FANCA/ fibroblasts
stably expressing GFP-FANCA (green). Spindle microtubules were visualized with anti-a-tubulin antibody (red), and DNAwas counterstained with Hoechst
33342 (blue). Area of interest was marked with a yellow square. Fluorescence intensity profile was visualized along the white dotted line. Bars 5 3 mm (left)
and 300 nm (right). (B) Fluorescence intensity profiles depict GFP-FANCA and a-tubulin signal peaks at two centrosome/microtubule attachment sites (#1
and #2).
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Supplementary Figure E4. Endogenous FANCA co-localizes with pericentrin and g-tubulin during metaphase. Representative super-resolution SIM images
revealing co-localization of endogenous FANCA with pericentrin (A) and g-tubulin (B) in metaphase HeLa cells. White dotted lines indicate location of
fluorescence intensity profiles (right). Bars 5 2 mm (left) and 500 nm (right).
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Supplementary Figure E5. FANCA and pericentrin localization profile throughout the cell cycle. SIM images of HeLa cells stained with antibodies against
endogenous FANCA (red) and pericentrin (green) during interphase (A), prophase (B), metaphase (C), and anaphase (D). Centrosomes were marked with
yellow squares and enlarged in middle panels. FANCA and pericentrin fluorescence line intensity profiles are depicted for each cell cycle stage. Note high
overlap of FANCA and pericentrin peaks on mitotic centrosomes (B–D) compared with interphase centrosome (A). Bars5 3 mm (A–D, left) and 500 nm (A–
D, right).
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Supplementary Figure E6. FANCA localizes to the mother centriole during interphase. SIM images of primary patient FANCA/ fibroblasts stably ex-
pressing FANCA-GFP stained with the antibody against the mother centriole marker CEP170 (red) during (A) G1 and (B) S/G2 cell cycle phases. Hoechst
33342 was used to counterstain DNA. Areas of interest marked with yellow squares are magnified (right panels) to show co-localization of FANCA-GFP and
CEP170. Bars 5 5 mm (left) and 500 nm (right).
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Supplementary Figure E7. Taxol dose–response curves of FANCA/
and isogenic gene-corrected cells. FANCA/ cells are more sensitive
to taxol than FANCAþ cells in CFU assays (A) and manual cell count as-
says (B). Two-way analysis of variance with Sidak correction was used for
data analysis. Figure depicts pooled results of three separate experiments,
expressed as the mean 6 SEM in triplicate. *p # 0.05, **p # 0.01, ***p
# 0.001, ****p # 0.0001. ns 5 not significant.
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Supplementary Figure E8. Validation of taxol hypersensitivity in additional FANCA and FANCC patient fibroblast cell lines. Representative plates (A) and
quantification (B) from CFU assay in which FANCAþ and FANCA/ fibroblasts (patient line RA885) were exposed to low-dose taxol for 11 days. Error
bars represent means 6 SEM, and a two-way analysis of variance with Sidak correction was used to assess statistical significance. (C) Cell count assay of
FANCC/ (patient line WD-C1) cells and FANCCþ fibroblasts exposed to varying doses of taxol for 9 days. Statistical analysis was performed using Stu-
dent’s t test with Holm–Sidak correction.
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Supplementary Figure E9. Rescue of MMC hypersensitivity by FANCA gene correction in primary FANCA/ patient cells. (A) Representative CFU
assay plates of FANCA/ or gene-corrected fibroblasts treated with indicated concentrations of MMC. (B) Normalized colony-forming ability (top) of
FANCAþ or FANCA/ fibroblasts treated with indicated concentrations of MMC for 11 days. (C) Cell count assay (bottom) of FANCAþ and
FANCA/ fibroblasts. Six-well plates were seeded with 1  105 cells/well and treated with indicated doses of MMC for 9 days. Cell counts were manually
performed using a hemacytometer. Two-way ANOVA with Sidak correction was used for data comparison. Quantitation of data is representative of three
separate experiments, and results are means 6 SEM. *p # 0.05, **p # 0.01, ***p # 0.001, ***p # 0.0001. ns 5 not significant.
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Supplementary Figure E10. Baseline cell cycle evaluation in FANCA/ fibroblasts and FANCA-corrected isogenic cells. FANCA/ fibroblasts do not
show significant differences in G1 or G2/M cell cycle fractions quantified by PI flow cytometry (A), S-phase fraction quantified by EdU incorporation via
microscopy (B), and phospho-H3þ mitotic fraction quantified by flow cytometry (C) compared with isogenic gene-corrected cells. The increase in sponta-
neous micronucleation (D, E) is consistent with previous studies [5]. Representative deconvolution microscopy images of cells of indicated genotypes are
shown. Bar 5 6 mm. To quantify incidence of micronucleation, at least 500 cells/genotype were imaged via deconvolution microscopy as z stacks spanning
whole cells, and results were analyzed with Fisher’s exact test. For flow cytometry analysis, data generated in three independent experiments were pooled and
compared with two-tailed t tests. EdU incorporation counts were compared via two-way analysis of variation with Sidak’s multiple comparison test.
Supplementary Figure E11. Continued DNA replication in multinucle-
ated FANCA/ and gene-corrected cells. FANCA/ fibroblasts and
isogenic FANCA-corrected cells were treated with 1 nmol/L taxol for 9
days to induce multinucleation. Then, DNA replication in single-
nucleated and multinucleated cells was quantified in EdU incorporation as-
says as illustrated in Figure 7. Multinucleated cells continue to replicate
DNA on abnormal mitotic exit, which may promote further accumulation
of DNA damage in interphase-like multinucleated cells [6,7]. The fre-
quency of S-phase entry in multinucleated cells is not FANCA dependent
(p 5 1, Fisher’s exact test; n 5 551 FANCA/ cells and 379 FANCA-
corrected cells were analyzed).
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Supplementary Figure E12. Somatic mutations of FANCA and FANCC in human malignancies. Tumor samples harboring amino acid alterations resulting
from confirmed missense (circle), nonsense (square), and frameshift gene mutations (triangle) in coding regions of FANCA (left) or FANCC (right) are
shown. Mutations with predicted protein functional impact are formatted in bold red, whereas mutations unlikely to affect protein function are in black.
Cancers associated with indicated mutations are on the left. Protein binding and phosphorylation sites of FANCA and FANCC are at the bottom.
SCC 5 squamous cell carcinoma; fs*4 5 frameshift that causes a translation stop four amino acids after the insertion. *Nonsense mutation.
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